On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

A groundbreaking FDA approval has introduced a new treatment option specifically designed for colorectal cancer patients with ...

Iowa has its first confirmed case of H5N1 bird flu in a poultry farm worker, the state's public health department announced.

Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to ...

The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.

US pharma giant Pfizer on Friday revealed that the US Food and Drug Administration (FDA) has approved its Braftovi ...

Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...

Pfizer Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination ...

Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved BRAFTOVI (encorafenib) in combination with cetuximab ...

Intelligent Living Application Group Inc. (the "Company" or "Intelligent Living"), a premium lockset manufacturer and distributor headquartered in Hong Kong, today announced its unaudited financial ...

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.